Charitable Contributions in 2019

Posted:
2
January 2020

As the 2019 year comes to an end, we would like to recognize the substantial charitable contributions made by the Richmond Pharmacology team; including our staff, academic

As the 2019 year comes to an end, we would like to recognize the substantial charitable contributions made by the Richmond Pharmacology team; including our staff, academic partners, collaborators and volunteers.Various initiatives have been undertaken including homeless sleep outs, bake sales, marathon events and Christmas Jumper day; all to raise money for those less fortunate than ourselves.

We would like to personally thank two very special volunteers, who decided to donate the payment they received from their study participants to the British Heart Foundation.At Richmond Pharmacology, our ethos is to improve the standard of living for millions of people through our research.

It is through generous donations, initiatives, and partnerships like these, that we are able to achieve our mission.

Notable donations throughout the year have been made to the following Charities

Looking to next year, 2020 promises to be another exciting year for Richmond Pharmacology and we look forward to continuing our charitable endeavors.Read letter of thanks from Robes

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more